MX2022004972A - Quimica de conjugacion novedosa para el anticuerpo catalitico 38c2. - Google Patents
Quimica de conjugacion novedosa para el anticuerpo catalitico 38c2.Info
- Publication number
- MX2022004972A MX2022004972A MX2022004972A MX2022004972A MX2022004972A MX 2022004972 A MX2022004972 A MX 2022004972A MX 2022004972 A MX2022004972 A MX 2022004972A MX 2022004972 A MX2022004972 A MX 2022004972A MX 2022004972 A MX2022004972 A MX 2022004972A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- catalytic
- anttibody
- lys99
- conjugation chemistry
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona el anticuerpo catalítico 38C2 modificado con arilación del residuo de lisina reactivo (Lys99). El residuo Lys99 se arila con un compuesto de heteroaril metilsulfonilo tal como metilsulfona feniloxadiazol (MS-PODA). La invención también proporciona agentes conjugados con anticuerpos (por ejemplo, conjugados de fármacos y anticuerpos) que contienen un resto de agente que está conjugado de forma específica del sitio con 38C2 a través de un compuesto de metilsulfonilo. Además, en la invención se proporcionan métodos para preparar los agentes conjugados con anticuerpos y aplicaciones terapéuticas de los agentes conjugados con anticuerpos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962925051P | 2019-10-23 | 2019-10-23 | |
PCT/US2020/055768 WO2021080846A1 (en) | 2019-10-23 | 2020-10-15 | Novel conjugation chemistry for catalytic anttibody 38c2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022004972A true MX2022004972A (es) | 2022-07-19 |
Family
ID=75620018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022004972A MX2022004972A (es) | 2019-10-23 | 2020-10-15 | Quimica de conjugacion novedosa para el anticuerpo catalitico 38c2. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230012213A1 (es) |
EP (1) | EP4048311A1 (es) |
JP (1) | JP2022553415A (es) |
KR (1) | KR20220087519A (es) |
CN (1) | CN114846030A (es) |
AU (1) | AU2020369479A1 (es) |
BR (1) | BR112022007734A2 (es) |
CA (1) | CA3155908A1 (es) |
IL (1) | IL292440A (es) |
MX (1) | MX2022004972A (es) |
WO (1) | WO2021080846A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100021379A1 (en) * | 2006-06-29 | 2010-01-28 | The Regents Of The University Of California | Chemical Antibodies for Immunotherapy and Imaging |
WO2014144878A2 (en) * | 2013-03-15 | 2014-09-18 | The Scripps Research Institute | Novel thiol & amino modifying reagents for protein chemistry and methods of use thereof |
EP3349795B1 (en) * | 2015-09-17 | 2021-03-17 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
-
2020
- 2020-10-15 KR KR1020227017353A patent/KR20220087519A/ko unknown
- 2020-10-15 EP EP20879521.1A patent/EP4048311A1/en active Pending
- 2020-10-15 AU AU2020369479A patent/AU2020369479A1/en active Pending
- 2020-10-15 US US17/770,922 patent/US20230012213A1/en active Pending
- 2020-10-15 WO PCT/US2020/055768 patent/WO2021080846A1/en unknown
- 2020-10-15 CN CN202080089851.1A patent/CN114846030A/zh active Pending
- 2020-10-15 IL IL292440A patent/IL292440A/en unknown
- 2020-10-15 MX MX2022004972A patent/MX2022004972A/es unknown
- 2020-10-15 CA CA3155908A patent/CA3155908A1/en active Pending
- 2020-10-15 JP JP2022524147A patent/JP2022553415A/ja active Pending
- 2020-10-15 BR BR112022007734A patent/BR112022007734A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2020369479A8 (en) | 2022-06-09 |
KR20220087519A (ko) | 2022-06-24 |
EP4048311A1 (en) | 2022-08-31 |
WO2021080846A1 (en) | 2021-04-29 |
CN114846030A (zh) | 2022-08-02 |
CA3155908A1 (en) | 2021-04-29 |
BR112022007734A2 (pt) | 2022-07-12 |
US20230012213A1 (en) | 2023-01-12 |
IL292440A (en) | 2022-06-01 |
WO2021080846A8 (en) | 2022-05-27 |
AU2020369479A1 (en) | 2022-05-26 |
JP2022553415A (ja) | 2022-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018058902A (ja) | 生体直交型薬物活性化 | |
Christie et al. | Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides | |
JP6533222B2 (ja) | 新規の抗体−薬剤コンジュゲート及び治療におけるその使用 | |
ES2758506T3 (es) | Péptidos citotóxicos y conjugados de estos | |
WO2014081303A1 (en) | Chemically cleavable group | |
PE20061439A1 (es) | DERIVADOS DE 2-AMIDO-6-AMINO-8-OXO-PURINA COMO MODULADORES DEL RECEPTOR Toll (TLR) | |
MX2021015221A (es) | Compuestos de aminobenzazepina, inmunoconjugados y usos de estos. | |
AR078470A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
PA8626201A1 (es) | Conjugados de caliqueamicina | |
CY1117729T1 (el) | Μεθοδοι για την παρασκευη κυτταροτοξικων συζευγματων μεϋτανσινοειδων και παραγοντων δεσμευσης κυτταρου | |
PE20140833A1 (es) | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo | |
WO2016064749A3 (en) | Antibody-drug conjugates and related compounds, compositions, and methods of use | |
SG10201810743WA (en) | Conjugation methods | |
PE20110008A1 (es) | Triazolopiridazinas como moduladores de quinasa | |
JP2023082171A (ja) | 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート | |
MX2022003740A (es) | Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos. | |
PE20170917A1 (es) | Anticuerpos anti-mesotelina e inmunoconjugados | |
EA201270625A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
RU2009117642A (ru) | Применение спирооксиндоловых соединений в качестве терапевтических средств | |
GT200800277A (es) | Derivados de leptomicina | |
CL2009000394A1 (es) | Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
ES2668645T3 (es) | Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B | |
DK1874818T3 (da) | TGF-Beta 1-specifikke antistoffer | |
PE20121534A1 (es) | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo | |
WO2017180789A8 (en) | Methods of treatment using chlorotoxin conjugates |